Nishi Shah

Nishi Shah


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
Amit VermaAmit Verma
Amit Verma
RSRajasekhar N.V.S. Suragani
Rajasekhar N.V.S. Suragani
SASrinivas Aluri
Srinivas Aluri
NSNishi Shah
Nishi Shah
TBTushar D. Bhagat
Tushar D. Bhagat
RKRavi Kumar
Ravi Kumar
Signaling by the TGF-β superfamily is important in the regulation of hematopoiesis and is dysregulated in myelodysplastic syndromes (MDSs), contributing to ineffective hematopoiesis and clinical cytopenias. TGF-β, activins, and growth differentiation factors exert inhibitory effects on red cell formation by activating canonical SMAD2/3 pathway signaling. In this Review, we summarize evidence that overactivation of SMAD2/3 signaling pathways in MDSs causes anemia due to impaired erythroid maturation. We also describe the basis for biological activity of activin receptor ligand traps, novel fusion proteins such as luspatercept that are promising as erythroid maturation agents to alleviate anemia and related comorbidities in MDSs and other conditions characterized by impaired erythroid maturation.

22 February 2024 in Haematologica
Verified
Journal Article
Open access
PDF file
MFMark Forsberg
Mark Forsberg
SBSantiago Beltran
Santiago Beltran
MGMendel Goldfinger
Mendel Goldfinger
MJMurali Janakiram
Murali Janakiram
DKDeepak Kalbi
Deepak Kalbi
NSNishi Shah
Nishi Shah

26 October 2023 in Haematologica
Verified
Journal Article
Open access
PDF file
JWJohn X. Wei
John X. Wei
ASAditi Shastri
Aditi Shastri
RSR. Alejandro Sica
R. Alejandro Sica
IMIoannis Mantzaris
Ioannis Mantzaris
NKNoah Kornblum
Noah Kornblum
NSNishi Shah
Nishi Shah
Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival.1,2 However, a notable proportion of patients continue to experience early mortality (EM), defined as 2 years from the time of diagnosis. This raises the possibility that improvements in myeloma survival have not extended equally to all groups. Using the latest data drawn from the Surveillance Epidemiology and End Results database of patients in the United States spanning 2000-2019, we study impact of important sociodemographic factors on EM. Through regression modeling, we demonstrate that patients diagnosed from 2000-2005, of older age, male sex, and of certain racial minority status (non-Hispanic Black and Hispanic) have higher odds of EM. Of these factors, minority status contributed to worse 2-year overall survival as well. We evaluate whether income, as a surrogate to access to care, could potentially explain this finding, but find that race has a distinct relationship with EM that is not modified by income. This is further reinforced by subgroup analysis. After characterizing groups vulnerable to EM, we examine reasons for these disparities and potential avenues to address them.

30 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZCZhu CUI
Zhu CUI
FCFrancesco Castagna
Francesco Castagna
WHWaqas Hanif
Waqas Hanif
SASamuel Joseph Apple
Samuel Joseph Apple
LZLili Zhang
Lili Zhang
LSLeandro Slipczuk
Leandro Slipczuk
Patients with multiple myeloma (MM) are at a high risk for developing cardiovascular complications. Global longitudinal strain (GLS) can detect early functional impairment before structural abnormalities develop. It remains unknown if reduced GLS is associated with reduced survival in patients with MM. We conducted a retrospective cohort analysis of patients diagnosed with MM between 1 January 2000 and 31 December 2017 at our institution. Patients with a 2D transthoracic echocardiogram completed within 1 year of MM diagnosis, left ventricular ejection fraction (LVEF) greater than 40%, and no history of myocardial infarction prior to MM diagnosis were included. GLS was measured using an artificial-intelligence-powered software (EchoGo Core), with reduced GLS defined as an absolute value of 9.6, LVEF/GLS > 4.1, higher LV mass index, and low-voltage ECG. A Total of 126 (52.1%) deaths occurred during follow-up. Overall survival was lower among patients with reduced GLS (adjusted HR: 1.81, CI: 1.07–3.05).